简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2021-10-12 19:30 DentalMonitoring Launches the ScanBoxpro, the New Version of Their Patented Device to Maximize AI-powered Control of Dental and Orthodontic Care Anywhere, Anytime
2021-10-12 18:53 Kaneka Releases PCR Test Kit for COVID-19 Variants
2021-10-12 18:10 BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma
2021-10-12 15:17 Crown Bioscience Launches ‘3D Ex Vivo Patient Tissue Platform’ to Improve Response Predictability to Immuno-Oncology Drug Candidates
2021-10-12 15:15 Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement
2021-10-12 13:14 Vifor Pharma announces changes to its Executive Committee
2021-10-12 10:07 BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
2021-10-11 16:33 BVI Announces Investment & Collaboration with Beyeonics Vision
2021-10-11 15:41 Takeda Provides Update on TAK-994 Clinical Program
2021-10-11 13:49 Mawi DNA Technologies Announces Partnership with FUJIFILM
2021-10-11 11:40 SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
2021-10-11 09:49 Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
2021-10-09 10:58 Exscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements
2021-10-08 21:06 Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud
2021-10-08 14:57 FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
2021-10-08 14:23 Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
2021-10-08 09:19 LianBio Appoints Michael Humphries as Chief Scientific Advisor
2021-10-08 09:16 Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021
2021-10-08 08:48 Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK
2021-09-30 19:29 "Ninja Diet" by Sideranch Inc. Published: Learn the Secrets of Dieting as a Ninja

Business Wire Weibo

Press Releases

Latest Releases